- Home
- SHO vs ZLAB Comparison
SHO vs ZLAB Comparison
Compare SHO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHO | ZLAB |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | China |
| Employees | 37 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SHO | ZLAB |
|---|---|---|
| Price | $9.01 | $20.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $9.28 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.4M | 696.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $4.13 | $14.46 |
| Revenue Next Year | $2.02 | $29.47 |
| P/E Ratio | $966.33 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $7.45 | $15.96 |
| 52 Week High | $10.01 | $44.34 |
Technical Indicators
Market Signals| Indicator | SHO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 62.72 |
| Support Level | $8.70 | $17.11 |
| Resistance Level | $9.38 | $27.23 |
| Average True Range (ATR) | 0.20 | 0.67 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 26.79 | 89.28 |
Price Performance
Historical ComparisonAbout SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.